Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013–2018

BACKGROUND: In 2019, the World Health Organization released guidelines reflecting major changes in multidrug-resistant tuberculosis (MDR-TB) management—prioritizing fluoroquinolones, bedaquiline, and linezolid (LZD) while de-emphasizing previously favored injectable agents. In some cases, linezolid...

Descripción completa

Detalles Bibliográficos
Autores principales: McDowell, Ashley, Haas, Michelle, Seaworth, Barbara, Wilson, John W., Patrawalla, Amee, Haley, Connie, Lauzardo, Mike, de Bruyn, Miko, Goswami, Neela D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732868/
https://www.ncbi.nlm.nih.gov/pubmed/33336084
http://dx.doi.org/10.1016/j.jctube.2020.100201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732868/
https://www.ncbi.nlm.nih.gov/pubmed/33336084
http://dx.doi.org/10.1016/j.jctube.2020.100201

Ejemplares similares